Ascentage Pharma Announces First Patient Dosed in Europe in the Phase Ib/II Study of the Bcl-2 inhibitor APG-2575 in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
LLS may be able to help pay your insurance premiums and co-pays if you are in active treatment or are being monitored for watch and wait or follow up care.
Learn more about the CLL fund.
For details on what’s covered and how to apply, click here: https://www.lls.org/support/financial-support/co-pay-assistance-program
Related posts